ISRCTN12623932 https://doi.org/10.1186/ISRCTN12623932

Evaluation of a dermocosmetic regimen for acne-prone skin in volunteers with mild, moderate or severe skin conditions

Submission date
05/08/2026

Recruitment status
No longer recruiting

Registration date
06/08/2026

Overall study status
Ongoing

Last Edited
06/08/2026

Condition category
Skin and Connective Tissue Diseases

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[_] Results
[_] Individual participant data
[X] Record updated in last year

Plain English summary of protocol

Background and study aims
Acne is a common skin condition that can affect a person's appearance, confidence and quality of life. Many skincare products are available for acne-prone skin, but more evidence is needed to understand how well they work in real-world settings.

This study aims to evaluate the effectiveness and tolerability of a dermocosmetic skincare regimen consisting of Eucerin DermoPure products and Eucerin Oil Control Sun Protection SPF50+ in people with mild to severe acne-prone skin.

Who can participate?
People aged 12 to 50 years with mild to severe acne-prone skin.

What does the study involve?
Up to 3,100 participants will take part worldwide.

Participants will be assigned to receive either:
A dermocosmetic skincare regimen based on the Eucerin DermoPure range together with sun protection or an active control skincare regimen.

Participants will attend a dermatologist clinic at the start of the study and again after 8 weeks. At these visits, the dermatologist will assess acne severity and count acne lesions.

Participants will:
Use the assigned skincare products at home for 8 weeks, take daily facial photographs and upload them electronically during the treatment period and complete questionnaires about their skin condition, quality of life and satisfaction with the products.

After the 8-week treatment period, participants will enter a maintenance phase lasting up to 10 months. During this time, they will complete monthly questionnaires and submit one facial photograph each month.

Total participation will last approximately 12 months.

What are the possible benefits and risks of participating?
Participants may experience an improvement in their acne and overall skin condition. The findings may help improve understanding of the effectiveness and tolerability of skincare regimens for acne-prone skin.

There is a possibility of side effects or skin reactions associated with the skincare products. Participants will be monitored throughout the study and any adverse events will be recorded.

Where is the study run from?
Multiple dermatology clinics and hospitals in the United Kingdom and other countries.

When is the study starting and how long is it expected to run for?
March 2025 to September 2026.

Who is funding the study?
Beiersdorf, Germany.

Who is the main contact?
Miss Anne-Christin Worthmann, Anne-Christin.Worthmann@Beiersdorf.com

Contact information

Type(s)
Scientific, Public

Contact name
Miss Anne-Christin Worthmann

Contact details
Beiersdorf AG, Head Office
Hamburg
Germany
22529
+49 40 4909 2116
Anne-Christin.Worthmann@Beiersdorf.com

Type(s)
Principal investigator

Contact name
Prof Viktoria Eleftheriadou

Contact details
Imperium Medical Limited, 10 Duckery Wood Walk
Birmingham
United Kingdom
B43 7DW
+44 7912530381
viktoria.eleftheriadou@nhs.net

Additional identifiers

Integrated Research Application System (IRAS)
348570

Study information

Scientific Title
Evaluation of a dermocosmetic regimen for acne-prone skin in volunteers with IGA Grades 2-4

Study objectives
To evaluate the efficacy of a dermocosmetic regimen consisting of the DermoPure Probiotic Kit (cleansing gel, cleansing mask, hydrogel and oil suspension with probiotics) and Eucerin Oil Control Sun Protection SPF50+ in subjects with acne-prone skin (IGA grades 2-4), as measured by change in acne lesion count.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 13/01/2025, North West - Greater Manchester Central Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 0207 104 8084; gmcentral.rec@hra.nhs.uk), ref: 25/NW/0006

Primary study design
Interventional

Allocation
Non-randomized controlled trial

Masking
Blinded (masking used)

Control
Active

Assignment
Parallel

Purpose
Treatment

Study type(s)

Health condition(s) or problem(s) studied
Subjects with acne-prone skin aged 12-50 years with Investigator's Global Assessment (IGA) grades 2-4, evaluating treatment of mild to severe acne vulgaris.

Interventions

Multicentre, blinded, non-randomised, active-controlled, parallel-group real-world evidence study in participants aged 12-50 years with acne-prone skin (IGA grades 2-4). Participants receive either a DermoPure Probiotic Kit-based dermocosmetic regimen plus sun protection or an active control skincare regimen. Clinical assessments are conducted at baseline and week 8, with participant questionnaires completed at baseline, week 4, week 8 and monthly until month 12. The primary outcome is change in acne lesion count; secondary outcomes include IGA score, participant satisfaction, quality of life, overall skin condition and safety.

Intervention Type
Other

Primary outcome(s)
1. Acne lesion count measured using an objective dermatologist-assessed count of inflammatory and non-inflammatory acne lesions on the face at Baseline (week 0) and Week 8; primary endpoint assessed as change from baseline to Week 8

Key secondary outcome(s)
1. Improvement in Investigator's Global Assessment (IGA) score measured using Dermatologist-assessed IGA acne severity score (0-4 scale) at Baseline and Week 8

2. Subject satisfaction with treatment, including product performance and satisfaction measured using subject self-assessment questionnaires at Week 8

3. Tolerability and safety measured using incidence and assessment of adverse events (AEs), serious adverse events (SAEs), and adverse product effects at Throughout the study (baseline to Month 12)

4. Overall skin condition measured using Subject self-grading questionnaires of skin condition using rating scales at Baseline, Week 4, Week 8, and monthly during Months 3-12

5. Quality of life measured using Cardiff Acne Disability Index (CADI) and Eucerin Quality of Life (ELQI) questionnaires at Baseline, Week 4, Week 8, and monthly during Months 3-12

Completion date
30/09/2026

Eligibility

Key inclusion criteria
1. Subjects aged 12-50 years
2. Gender: Male, Female, Diverse
3. Phototype Fitzpatrick I-VI
4. Acne-prone skin with IGA grades 2-4
5. Generally healthy, with intact facial skin except for acne lesions
6. Willingness and ability to sign informed consent
7. Compliance with study rules and schedule

Healthy volunteers allowed
No

Age group

Mixed

Lower age limit
12 Years

Upper age limit
50 Years

Sex
All

Total final enrolment
3100

Key exclusion criteria
1. Pregnant or lactating women
2. Damaged facial skin (e.g., sunburn, eczema)
3. Use of topical antibiotics or benzoyl peroxide (BPO) during the study
4. Fungal acne
5. Chronic skin diseases, recent (4 weeks before study start) use of immunosuppressants, corticosteroids, or other treatments that could interfere with study outcomes
6. Any dermatological procedures (e.g., peeling, laser treatments) within 2 months prior to the study
7. Participation in any study within the last 3 months

Date of first enrolment
13/03/2025

Date of final enrolment
14/04/2026

Locations

Countries of recruitment
United Kingdom

England

Austria

Belgium

Brazil

Bulgaria

Chile

Colombia

Croatia

Czech Republic

Ecuador

France

Germany

Hungary

Italy

Malaysia

Mexico

Netherlands

Peru

Poland

Portugal

Serbia

Slovakia

South Africa

Spain

Switzerland

Thailand

Viet Nam

Study participating centre
Chelsea and Westminster Private Dermatology Clinic
369 Fulham Rd
London
England
SW10 9NH

Study participating centre
Homerton Hospital
Homerton Row

London
England
E9 6SR

Study participating centre
Imperium Medical Ltd
10 Duceery Wood Walk
Birmingham
England
B43 7DW

Study participating centre
Miravue Clinic - Sangeeta Punjabi
Spikesbridge Road
Southall
England
UB1 2AS

Study participating centre
Nuffield Health Warwick
Gallagher Business Park
Heathcote
England
CV34 6AD

Study participating centre
Simon Tso
16 Hillmorton Road
Rugby
England
CV22 5AA

Study participating centre
Hospital of St John and St Elizabeth (grove End Road)
60 Grove End Road
London
England
NW8 9NH

Study participating centre
Taktouk Clinic
12 Sloane St
London
England
SW1X 9LJ

Study participating centre
The Meriden Hospital, Part of Circle Health Group
University Hospital site, Clifford Bridge Rd
Coventry
England
CV22LQ

Sponsor information

Organisation
Beiersdorf (Germany)

ROR
https://ror.org/04aqg9s78

Funder(s)

Funder type

Funder Name
Beiersdorf

Alternative Name(s)

Funding Body Type
Private sector organisation

Funding Body Subtype
For-profit companies (industry)

Location
Germany

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available